Combined Treatment of Resistant Hypertension and Atrial Fibrillation

Meshalkin Research Institute of Pathology of Circulation

Status and phase

Completed

Phase 2

Conditions

Atrial Fibrillation

Hypertension, Resistant to Conventional Therapy

Treatments

Procedure: Circumferential PV isolation

Procedure: Circumferential PVI+renal denervation

Study type

Interventional

Funder types

NETWORK

Identifiers

NCT01117025

RU MC 001 (Other Identifier)

RDAFA-029

Details and patient eligibility

About

The purpose of this study is the comparative evaluation of systolic blood pressure (SBP) lowering, atrial fibrillation (AF) recurrence and clinical data in patients with paroxysmal/persistent AF and resistant hypertension, undergoing AF ablation alone or combined with percutaneous renal denervation.

Enrollment

26 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Symptomatic drug-refractory AF (with history of failure of ≥2 class I or III antiarrhythmic drugs) in patients referred for catheter ablation of AF
PAF with ≥1 monthly episodes or PersAF in patients who had already undergone ≥3 electrical cardioversions. PAF was defined as episodes lasting less than 7 days with spontaneous termination. PersAF was defined as lasting more than 7 days before being terminated pharmacologically or by electrical cardioversion.
Office-based systolic blood pressure of ≥160 mm Hg, despite treatment with ≥3 antihypertensive drugs (including 1 diuretic)
A glomerular filtration rate ≥45 mL/min/1⋅73 m2, with modification of diet using a renal disease formula

Exclusion criteria